Weekly Recap: Zorevunersen 2028 approval goal and Edward Kaye retirement

Stoke Therapeutics, Inc. (NASDAQ:STOK) said its antisense therapy zorevunersen aims to boost NaV1.1 in brain cells for a disease—modifying Dravet syndrome treatment with approval targeted around early 2028, as director Edward Kaye, M.D. retires from the board but stays on as an advisor.Previous Wee…